New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTPRXL, SGYPSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
07:40 EDTSGYPSynergy Pharmaceuticals initiated with a Buy at BTIG
Subscribe for More Information
August 17, 2015
11:13 EDTPRXLPAREXEL calls active on wide price movement
Subscribe for More Information
11:01 EDTPRXLPAREXEL jumps 9% to $74.44 in morning trading
Subscribe for More Information
August 14, 2015
17:44 EDTSGYPSynergy up 2.65% after Paulson reports raised stake in company in 13F filing
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use